Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Jul 4. pii: noz119. doi: 10.1093/neuonc/noz119. [Epub ahead of print]

PMID:
31276167
2.

Hyperphosphorylation of CDH1 in Glioblastoma Cancer Stem Cells Attenuates APC/CCDH1 Activity and Pharmacologic Inhibition of APC/CCDH1/CDC20 Compromises Viability.

De K, Grubb TM, Zalenski AA, Pfaff KE, Pal D, Majumder S, Summers MK, Venere M.

Mol Cancer Res. 2019 Jul;17(7):1519-1530. doi: 10.1158/1541-7786.MCR-18-1361. Epub 2019 Apr 29.

PMID:
31036696
3.

Quantitative characterization of the regulation of iron metabolism in glioblastoma stem-like cells using magnetophoresis.

Park KJ, Kim J, Testoff T, Adams J, Poklar M, Zborowski M, Venere M, Chalmers JJ.

Biotechnol Bioeng. 2019 Jul;116(7):1644-1655. doi: 10.1002/bit.26973. Epub 2019 Apr 24.

PMID:
30906984
4.

A Pilot Study to Investigate the Balance between Proteases and α1-Antitrypsin in Bronchoalveolar Lavage Fluid of Lung Transplant Recipients.

Cagnone M, Piloni D, Ferrarotti I, Di Venere M, Viglio S, Magni S, Bardoni A, Salvini R, Fumagalli M, Iadarola P, Martinello S, Meloni F.

High Throughput. 2019 Feb 13;8(1). pii: E5. doi: 10.3390/ht8010005.

5.

The lomustine crisis: awareness and impact of the 1500% price hike.

Taylor JW, Armstrong T, Kim AH, Venere M, Acquaye A, Schrag D, Wen PY.

Neuro Oncol. 2019 Jan 1;21(1):1-3. doi: 10.1093/neuonc/noy189. No abstract available.

PMID:
30590836
6.

Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.

Jarrar A, Lotti F, DeVecchio J, Ferrandon S, Gantt G, Mace A, Karagkounis G, Orloff M, Venere M, Hitomi M, Lathia J, Rich JN, Kalady MF.

Stem Cells. 2019 Jan;37(1):42-53. doi: 10.1002/stem.2929. Epub 2018 Nov 12.

PMID:
30353615
7.

USP14 regulates DNA damage repair by targeting RNF168-dependent ubiquitination.

Sharma A, Alswillah T, Singh K, Chatterjee P, Willard B, Venere M, Summers MK, Almasan A.

Autophagy. 2018;14(11):1976-1990. doi: 10.1080/15548627.2018.1496877. Epub 2018 Aug 10.

8.

A posttranslational modification of the mitotic kinesin Eg5 that enhances its mechanochemical coupling and alters its mitotic function.

Muretta JM, Reddy BJN, Scarabelli G, Thompson AF, Jariwala S, Major J, Venere M, Rich JN, Willard B, Thomas DD, Stumpff J, Grant BJ, Gross SP, Rosenfeld SS.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1779-E1788. doi: 10.1073/pnas.1718290115. Epub 2018 Feb 5. Erratum in: Proc Natl Acad Sci U S A. 2018 Mar 5;:.

9.

Not just another biomarker: the role of integrin alpha 7 in glioblastoma.

Zalenski A, De K, Venere M.

Stem Cell Investig. 2017 Dec 20;4:99. doi: 10.21037/sci.2017.12.02. eCollection 2017. No abstract available.

10.

Advances in the analysis of "less-conventional" human body fluids: An overview of the CE- and HPLC-MS applications in the years 2015-2017.

Di Venere M, Viglio S, Cagnone M, Bardoni A, Salvini R, Iadarola P.

Electrophoresis. 2018 Jan;39(1):160-178. doi: 10.1002/elps.201700276. Epub 2017 Sep 1. Review.

PMID:
28792066
11.

Self-tanning cells, the new SPF.

Venere M.

Sci Transl Med. 2017 Jul 5;9(397). pii: eaan8202. doi: 10.1126/scitranslmed.aan8202.

PMID:
28679660
12.

A GEMA of a personalized medicine strategy.

Venere M.

Sci Transl Med. 2017 May 24;9(391). pii: eaan4294. doi: 10.1126/scitranslmed.aan4294.

PMID:
28539474
13.

Getting down to the FACT: therapeutic targeting of MYC-dependent tumors.

Venere M.

Ann Transl Med. 2017 Apr;5(7):174. doi: 10.21037/atm.2017.03.46. No abstract available.

14.

Vitamin C puts the pedal to the metal.

Venere M.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaan2778. doi: 10.1126/scitranslmed.aan2778.

PMID:
28404860
15.

Astrocytes light up glial heterogeneity.

Venere M.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaam9858. doi: 10.1126/scitranslmed.aam9858.

PMID:
28251910
16.

Do the complementarities of electrokinetic and chromatographic procedures represent the "Swiss knife" in proteomic investigation? An overview of the literature in the past decade.

Di Venere M, Viglio S, Sassera D, Fumagalli M, Bardoni A, Salvini R, Cagnone M, Iadarola P.

Electrophoresis. 2017 Jun;38(12):1538-1550. doi: 10.1002/elps.201600504. Epub 2017 Feb 21. Review.

PMID:
28130906
17.

Self-contained microfluidic systems: a review.

Boyd-Moss M, Baratchi S, Di Venere M, Khoshmanesh K.

Lab Chip. 2016 Aug 16;16(17):3177-92. doi: 10.1039/c6lc00712k. Review.

PMID:
27425637
18.

Chromosomal Instability Affects the Tumorigenicity of Glioblastoma Tumor-Initiating Cells.

Godek KM, Venere M, Wu Q, Mills KD, Hickey WF, Rich JN, Compton DA.

Cancer Discov. 2016 May;6(5):532-45. doi: 10.1158/2159-8290.CD-15-1154. Epub 2016 Mar 21.

19.

Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.

Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, Purmal AA, Gurova KV, Rich JN, Lathia JD, Stark GR, Venere M.

Cancer Res. 2016 Apr 15;76(8):2432-42. doi: 10.1158/0008-5472.CAN-15-2162. Epub 2016 Feb 26.

20.

Ixodes ricinus and Its Endosymbiont Midichloria mitochondrii: A Comparative Proteomic Analysis of Salivary Glands and Ovaries.

Di Venere M, Fumagalli M, Cafiso A, De Marco L, Epis S, Plantard O, Bardoni A, Salvini R, Viglio S, Bazzocchi C, Iadarola P, Sassera D.

PLoS One. 2015 Sep 23;10(9):e0138842. doi: 10.1371/journal.pone.0138842. eCollection 2015.

21.

Multi-object segmentation framework using deformable models for medical imaging analysis.

Namías R, D'Amato JP, Del Fresno M, Vénere M, Pirró N, Bellemare ME.

Med Biol Eng Comput. 2016 Aug;54(8):1181-92. doi: 10.1007/s11517-015-1387-3. Epub 2015 Sep 21.

PMID:
26392182
22.

The mitotic kinesin KIF11 is a driver of invasion, proliferation, and self-renewal in glioblastoma.

Venere M, Horbinski C, Crish JF, Jin X, Vasanji A, Major J, Burrows AC, Chang C, Prokop J, Wu Q, Sims PA, Canoll P, Summers MK, Rosenfeld SS, Rich JN.

Sci Transl Med. 2015 Sep 9;7(304):304ra143. doi: 10.1126/scitranslmed.aac6762.

23.

Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance.

Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, Alvarado A, Caplan AI, Rich J, Gerson SL, Lathia J, Liu H.

Cancer Res. 2015 Mar 15;75(6):924-9. doi: 10.1158/0008-5472.CAN-14-3225. Epub 2015 Jan 20. Review.

24.

Automatic rectum limit detection by anatomical markers correlation.

Namías R, D'Amato JP, del Fresno M, Vénere M.

Comput Med Imaging Graph. 2014 Jun;38(4):245-50. doi: 10.1016/j.compmedimag.2014.01.005. Epub 2014 Feb 1.

PMID:
24598410
25.

Coordinated regulation of p31(Comet) and Mad2 expression is required for cellular proliferation.

Date DA, Burrows AC, Venere M, Jackson MW, Summers MK.

Cell Cycle. 2013 Dec 15;12(24):3824-32. doi: 10.4161/cc.26811. Epub 2013 Oct 15.

26.

Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells.

Venere M, Hamerlik P, Wu Q, Rasmussen RD, Song LA, Vasanji A, Tenley N, Flavahan WA, Hjelmeland AB, Bartek J, Rich JN.

Cell Death Differ. 2014 Feb;21(2):258-69. doi: 10.1038/cdd.2013.136. Epub 2013 Oct 11.

27.

Changing the fate of cancer, one splice at a time.

Schonberg DL, Venere M, Rich JN.

Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14510-1. doi: 10.1073/pnas.1313419110. Epub 2013 Aug 22. No abstract available.

28.

Growth factor receptors define cancer hierarchies.

Venere M, Lathia JD, Rich JN.

Cancer Cell. 2013 Feb 11;23(2):135-7. doi: 10.1016/j.ccr.2013.01.020.

29.

Mitotic control of cancer stem cells.

Venere M, Miller TE, Rich JN.

Cancer Discov. 2013 Feb;3(2):141-4. doi: 10.1158/2159-8290.CD-12-0588.

30.

Laminin alpha 2 enables glioblastoma stem cell growth.

Lathia JD, Li M, Hall PE, Gallagher J, Hale JS, Wu Q, Venere M, Levy E, Rani MR, Huang P, Bae E, Selfridge J, Cheng L, Guvenc H, McLendon RE, Nakano I, Sloan AE, Phillips HS, Lai A, Gladson CL, Bredel M, Bao S, Hjelmeland AB, Rich JN.

Ann Neurol. 2012 Nov;72(5):766-78. doi: 10.1002/ana.23674.

31.

Sox1 marks an activated neural stem/progenitor cell in the hippocampus.

Venere M, Han YG, Bell R, Song JS, Alvarez-Buylla A, Blelloch R.

Development. 2012 Nov;139(21):3938-49. doi: 10.1242/dev.081133. Epub 2012 Sep 19. Erratum in: Development. 2012 Nov;139(21):4094.

32.

HeMoLab--Hemodynamics Modelling Laboratory: an application for modelling the human cardiovascular system.

Larrabide I, Blanco PJ, Urquiza SA, Dari EA, Vénere MJ, de Souza e Silva NA, Feijóo RA.

Comput Biol Med. 2012 Oct;42(10):993-1004. doi: 10.1016/j.compbiomed.2012.07.011. Epub 2012 Sep 8.

33.

Glioma stem cell maintenance: the role of the microenvironment.

Heddleston JM, Hitomi M, Venere M, Flavahan WA, Yang K, Kim Y, Minhas S, Rich JN, Hjelmeland AB.

Curr Pharm Des. 2011;17(23):2386-401. Review.

34.

Deadly teamwork: neural cancer stem cells and the tumor microenvironment.

Lathia JD, Heddleston JM, Venere M, Rich JN.

Cell Stem Cell. 2011 May 6;8(5):482-5. doi: 10.1016/j.stem.2011.04.013. Review.

35.

Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy.

Venere M, Fine HA, Dirks PB, Rich JN.

Glia. 2011 Aug;59(8):1148-54. doi: 10.1002/glia.21185. Epub 2011 May 5. Review.

36.

Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology?

Lathia JD, Venere M, Rao MS, Rich JN.

Stem Cell Rev Rep. 2011 Jun;7(2):227-37. doi: 10.1007/s12015-010-9194-6. Review.

37.

The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for cardiac development in mice.

Mayers CM, Wadell J, McLean K, Venere M, Malik M, Shibata T, Driggers PH, Kino T, Guo XC, Koide H, Gorivodsky M, Grinberg A, Mukhopadhyay M, Abu-Asab M, Westphal H, Segars JH.

J Biol Chem. 2010 Apr 16;285(16):12344-54. doi: 10.1074/jbc.M110.106856. Epub 2010 Feb 5.

38.

Embryonic stem cell-specific microRNAs promote induced pluripotency.

Judson RL, Babiarz JE, Venere M, Blelloch R.

Nat Biotechnol. 2009 May;27(5):459-61. doi: 10.1038/nbt.1535. Epub 2009 Apr 12.

39.

A combined region growing and deformable model method for extraction of closed surfaces in 3D CT and MRI scans.

del Fresno M, Vénere M, Clausse A.

Comput Med Imaging Graph. 2009 Jul;33(5):369-76. doi: 10.1016/j.compmedimag.2009.03.002. Epub 2009 Apr 5.

PMID:
19346100
40.

Generation of induced pluripotent stem cells in the absence of drug selection.

Blelloch R, Venere M, Yen J, Ramalho-Santos M.

Cell Stem Cell. 2007 Sep 13;1(3):245-7. doi: 10.1016/j.stem.2007.08.008. Epub 2007 Sep 6. No abstract available.

41.
42.

Evaluation of claspin as a proliferation marker in human cancer and normal tissues.

Tsimaratou K, Kletsas D, Kastrinakis NG, Tsantoulis PK, Evangelou K, Sideridou M, Liontos M, Poulias I, Venere M, Salmas M, Kittas C, Halazonetis TD, Gorgoulis VG.

J Pathol. 2007 Feb;211(3):331-9.

PMID:
17152083
43.

SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response.

Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman NE, Pagano M.

Mol Cell. 2006 Aug 4;23(3):319-29.

44.

Valosin-containing protein phosphorylation at Ser784 in response to DNA damage.

Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S, Williams A, Greulich H, Gardner J, Venere M, Mochan TA, DiTullio RA Jr, Moravcevic K, Gorgoulis VG, Burkhardt A, Halazonetis TD.

Cancer Res. 2005 Sep 1;65(17):7533-40.

45.

ATM signaling and 53BP1.

Zgheib O, Huyen Y, DiTullio RA Jr, Snyder A, Venere M, Stavridi ES, Halazonetis TD.

Radiother Oncol. 2005 Aug;76(2):119-22. Review.

PMID:
16024119
46.

Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD.

Nature. 2005 Apr 14;434(7035):907-13.

PMID:
15829965
47.

Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23.

MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T.

EMBO J. 2004 Sep 15;23(18):3689-99. Epub 2004 Sep 2.

48.

53BP1, an activator of ATM in response to DNA damage.

Mochan TA, Venere M, DiTullio RA Jr, Halazonetis TD.

DNA Repair (Amst). 2004 Aug-Sep;3(8-9):945-52.

PMID:
15279780
49.
50.

The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains.

Bothos J, Summers MK, Venere M, Scolnick DM, Halazonetis TD.

Oncogene. 2003 Oct 16;22(46):7101-7.

PMID:
14562038

Supplemental Content

Loading ...
Support Center